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ABSTRACT  1 
Primary aldosteronism (PA) is associated with an increased risk of cardiovascular events compared 2 
to essential hypertension (EH). Endothelial dysfunction is described as a marker of aldosterone-3 
dependent cardiovascular injury in patients with PA, as well as in EH. Circulating extracellular 4 
vesicles (EVs), reflecting endothelial cell activity, could represent one of the mediators of endothelial 5 
dysfunction in these patients. The aim of this study was to characterize for the first time circulating 6 
EVs from patients diagnosed with PA compared to controls with EH.  7 
Serum EVs were isolated from 12 patients with PA and 12 with EH, matched by sex, age and blood 8 
pressure. At nanoparticle tracking analysis, EVs concentration was 2.2 times higher in PA patients 9 
(P=0.011) compared with EH and a significant correlation between EV number and serum 10 
aldosterone levels was identified; fluorescence-activated cell sorting analysis demonstrated that 11 
42.1% of isolated EVs originated from leukocytes, 21.6% from endothelial cells, and 14.7% from 12 
platelets and that PA patients had a higher number of endothelial EVs compared to EH (P=0.005). 13 
Through EV mRNA profiling, 15 up-regulated and 4 down-regulated genes in PA patients compared 14 
to EH were identified; moreover, EDN1 was expressed only in patients with PA. Micro-array platform 15 
was validated by qRT-PCR on 4 genes (CASP1, EDN1, F2R, HMOX1) involved in apoptosis, 16 
inflammation and endothelial dysfunction. qRT-PCR confirmed the up-regulation of CASP1 and 17 
EDN1 (fold-change 12.0/18.3; P=0.023 and P=0.035, respectively).  18 
According to our results, circulating EVs may represent a marker of endothelial injury, involved in 19 
progression of organ damage in PA patients.  20 
 21 
Keywords: extracellular vesicles, primary aldosteronism, endothelial dysfunction, endothelin-1, 22 
caspase-1.  23 
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ABBREVIATION LIST  1 
NO, Nitric Oxide; ET-1 Endothelin-1; MR, Mineralocorticoid Receptor; PA, Primary Aldosteronism; 2 
BP, Blood Pressure; EVs, Extracellular Vesicles; EXOs, Exosomes; EH, Essential Hypertension; 3 
APA, Aldosterone Producing Adenoma; NTA, Nanoparticle Tracking Analysis; FACS analysis, 4 
Fluorescence-Activated Cell Sorting analysis;  5 
 6 
INTRODUCTION 7 
Endothelium is the inner layer of blood vessels and plays a key role in the regulation of peripheral 8 
arterial tone and vascular homeostasis1. Endothelial dysfunction results from the imbalance between 9 
vasodilators, such as nitric oxide (NO), and vasoconstrictors, such as angiotensin II and endothelin-10 
1 (ET-1)2. In addition to impaired vasoreactivity, endothelial failure determines a pro-inflammatory 11 
and pro-coagulatory state, favouring initiation and progression of atherosclerosis3; consistently, 12 
several studies demonstrated the association between endothelial dysfunction and cardiovascular 13 
events4. 14 
It is well known that an inappropriate aldosterone production for sodium status can induce not only 15 
arterial hypertension, but also detrimental effects on endothelium and vascular remodelling5. In fact, 16 
it has been reported that aldosterone treatment inhibits NO release in rat vascular smooth muscle 17 
cells6 and that aldosterone infusion promotes, in murine models, the impairment of endothelium-18 
dependent vasodilatation and the development of severe arterial hypertension and inflammatory 19 
response, with perivascular leukocyte infiltrate and fibrinoid necrosis of the tunica media7,8. The 20 
acute administration of aldosterone inhibits acetylcholine-induced endothelium-dependent 21 
vasodilatation in healthy volunteers9, whereas in patients with chronic heart failure (and hence 22 
secondary hyperaldosteronism), spironolactone administration improves endothelial function by 23 
increasing NO bioavailability10. Furthermore, patients with primary aldosteronism (PA) displayed 24 
aldosterone-related vascular inflammation and oxidative stress with endothelial dysfunction and 25 
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vascular damage11,12, which translated into increased arterial stiffness and loss of vascular 1 
reactivity11,13. The administration of a MR antagonist significantly improved endothelial function 2 
both in patients with PA and in control patients with resistant hypertension, independently from blood 3 
pressure (BP) decrease11.  4 
Extracellular vesicles (EVs) are bilayer membrane structures classified according to size and 5 
biogenesis in microvesicles and exosomes (EXOs); EXOs are the smaller and best characterized EVs, 6 
with a diameter ranging from 30 to 150 nm14. EVs are constitutively released by cells and they are 7 
involved in mechanisms of autocrine, paracrine and endocrine signaling through the transfer of 8 
proteins, lipids, and nucleic acids. The ability to transfer genetic information, thus influencing the 9 
behavior of target cells, makes EVs key players in inter-cellular communication14,15. EVs reflect the 10 
activation state of parent cell and may represent a valuable resource for the assessment of 11 
cardiovascular disease16; considering EVs as surrogate markers of endothelial cell 12 
function/dysfunction, we hypothesized that they could be one of the key mediators of endothelial 13 
dysfunction and aldosterone-mediated cardiovascular injury.  14 
PA is a frequent cause of endocrine hypertension with a prevalence of 5-10% among the hypertensive 15 
population17,18. Patients affected by PA display an increased prevalence of target organ damage and 16 
cardiovascular events compared to patients with EH19. Endothelial dysfunction may justify at least in 17 
part the increased cardiovascular risk in these patients; therefore, the aims of the present study were 18 
to characterize serum-derived EVs in patients with PA compared to controls with EH and to analyse 19 
their mRNA cargo in order to explore a potential role for EVs in aldosterone-mediated endothelial 20 
damage. 21 
 22 
METHODS 23 
A detailed description of patient selection, EV isolation and characterization protocols and gene 24 
expression analysis are provided in the online supplement. 25 
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Patient Selection 1 
We recruited 12 patients with PA due to an aldosterone producing adenoma (APA) and 12 patients 2 
affected by EH matched by gender, age and BP values, diagnosed at the Division of Internal Medicine 3 
and Hypertension Unit, University of Torino. Each patient underwent medical examination and 4 
routine laboratory tests. Diagnosis of PA was made according to the Endocrine Society guideline17. 5 
The study was approved by the local ethical committee and fully informed written consent was 6 
obtained from each patient. 7 
EVs isolation and characterization 8 
EVs were isolated from aliquot of serum using a charge-based precipitation method, as previously 9 
described20. To further purify EVs samples, we performed a second isolation step through 10 
ultracentrifugation at 100,000 g21. Isolated EVs were then carefully characterized by Nanoparticle 11 
Tracking Analysis (NTA), Fluorescence-Activated Cell Sorting (FACS) analysis and Western Blot. 12 
FACS analysis and NTA described EVs derivation (endothelial cells, platelets or leucocytes) and the 13 
number of EVs per mL with their relative size distribution, respectively. A Western Blot on protein 14 
lysate was performed in order to confirm the presence of EVs markers on analyzed samples (CD63, 15 
TSG101 and Flotillin-1). 16 
Gene expression analysis 17 
RNA extraction from purified EVs and total RNA retro-transcription were performed through 18 
commercially available kits (mirVana Isolation Kit, Thermo Fisher Scientific, Waltham, 19 
Massachusetts, USA; RT2 First Strand kit, Qiagen, Hilden, Germany), according to manufacturer’s 20 
instructions. mRNA qRT-PCR array profiling was performed on 4 patients diagnosed with PA and 4 21 
with EH, using a platform focused on the evaluation of 96 human genes involved in endothelial 22 
function regulation (Endothelial Cell Biology RT2 Profiler PCR Array Format E384, Qiagen, Hilden, 23 
Germany). The results were subsequently validated with qRT-PCR on 10 patients with PA and 10 24 
with EH (2 patients from each group were included also in qRT-PCR array analysis) for CASP1 25 
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(Caspase 1, Apoptosis-related Cysteine Peptidase), EDN1 (Endothelin 1), F2R (Coagulation factor II 1 
[thrombin] receptor) and HMOX1 (Heme Oxygenase [decycling] 1), selected considering their 2 
expression profile and available functional data in literature. Data were analyzed through a dedicated 3 
software, with the 2-ΔΔCT relative quantification (RQ) method, using 18SrRNA (18S ribosomal RNA) 4 
as endogenous control. The RQ mean gene expression of PA patients was compared to EH and 5 
expressed as fold-change (FC). A gene was considered down-regulated for FC values between 0 and 6 
1 or up-regulated for values greater than 1. 7 
Statistical Analysis 8 
IBM SPSS Statistics 22 (IBM Corp., Armonk, New York, USA) was used for statistical analyses. Data 9 
were analyzed with the Kolmogorov–Smirnov test to determine their distributions. Normally 10 
distributed variables (age, potassium, systolic and diastolic BP) are expressed as mean ± standard 11 
deviation; non-normally distributed variables (PRA, aldosterone, EVs-diameter and concentration, 12 
FACs analysis data and RQ) are expressed as median [interquartile range]. ANOVA one-way and 13 
Mann-Whitney’s tests were used to compare variables with a normal or non-normal distribution, 14 
respectively. Correlations were evaluated by Pearson test (R coefficient) and regression curve 15 
analysis. P-values of less than 0.05 were considered significant. 16 
 17 
RESULTS 18 
EVs characterization 19 
A total of 12 patients with PA and a subtype diagnosis of APA and 12 controls with EH, carefully 20 
matched by gender, age and BP values were included in the study; patient characteristics with 21 
hormonal parameters are described in Table 1. Each cohort was composed of 8 males and 4 females, 22 
with a mean age of 51 ± 8 years for PA patients and 50 ± 7 for EH patients (P = 0.809). As expected, 23 
BP values were similar (152/94 and 150/93 mmHg, respectively for patients with PA and EH; P > 24 
0.05), whereas patients with PA had lower potassium and PRA levels and higher aldosterone levels 25 
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(P < 0.001 for all comparison) compared with patients with EH. For each patient, serum-derived EVs 1 
were systematically characterized through NTA, FACS analysis and Western Blot for EV-markers 2 
(Figure 1).  3 
At NTA, patients with PA and EH showed a similar EV-diameter (respectively 250 nm [176; 262] 4 
and 233 nm [203; 265]; P = 0.874; Figure 1A), whereas the number of EVs per mL was significantly 5 
higher for patients with PA compared with patients with EH (7.8E+11 [6.2E+11; 3.0E+12] versus 6 
3.6E+11 [1.7E+11; 1.3E+12]; P = 0.011; Figure 1B).  7 
To define the origin of isolated EVs, we performed FACS analysis for three different surface markers: 8 
CD31 for endothelial cells, CD42b for platelets, and CD45 for leucocytes. In cytofluorimetric 9 
analysis each EV passes through the flow cytometer and is detected as a distinct event; we expressed 10 
EVs concentration as the number of events detected in 60 seconds. Most EVs resulted positive for 11 
CD45 (42.1%), whereas 21.6% and 14.7% were positive for CD31 and CD42b, respectively, without 12 
significant differences in percentage distribution between the two group of patients. Patients with PA 13 
presented a higher absolute number of endothelial-derived EVs (1545 [1161; 2151] versus 645 [508; 14 
1174] events per 60 seconds; P = 0.005), whereas we did not find differences for CD42b and CD45 15 
between patients with PA and EH (808 [564; 979] versus 415 [313; 778] events per 60 seconds – P= 16 
0.052 and 3091 [1970; 4531] versus 1460 [1108; 2542] events per 60 sec – P = 0.075, respectively). 17 
Consistent with NTA findings, the total absolute number of events per 60 seconds was significant 18 
higher in patients with PA compared with patients with EH (7642 [6375; 10391] vs 3450 [2464; 19 
4931]; P = 0.001; Figure 1C).  20 
The EV concentration was 2.2 times higher in patients with PA versus controls with both FACS 21 
analysis and NTA; furthermore, the number of EVs per mL directly correlated with aldosterone 22 
concentration (R = 0.472; P= 0.020). Conversely, we did not find a significant correlation with 23 
systolic (R = 0.347; P= 0.097) or diastolic BP (R = 0.308; P = 0.144, independently from the diagnosis 24 
(supplemental figure S1).  25 
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In order to confirm the presence of EVs in our samples, we also performed a Western Blot analysis 1 
that demonstrated the expression of EV markers CD63, TSG101 and Flotillin-1 (Figure 1D). 2 
 3 
Gene expression analysis 4 
To investigate a potential role for EVs in aldosterone-mediated endothelial damage in patients 5 
diagnosed with PA, we performed a qRT-PCR-array evaluating the expression level of a panel of 96 6 
human genes involved in angiogenesis, vasoconstriction / vasodilatation, inflammatory response, 7 
apoptosis, cell adhesion, coagulation and platelet activation; we compared 4 patients with PA with 4 8 
patients affected by EH. Considering both PA and EH cohorts, 63 genes were expressed in serum-9 
derived EVs of at least one patient (Supplementary Table S1). Among the 19 transcripts found in EVs 10 
of at least 4 of the 8 patients included in the analysis, 4 genes were down-regulated (CCL5 11 
[Chemokine (C-C motif) ligand 5], F3 [Coagulation factor III (thromboplastin)], ITGB1 [Integrin, 12 
beta 1], PDGFRA [PLT-derived GF receptor, alpha polypeptide]) and 15 were up-regulated (ANGPT1 13 
[Angiopoietin 1], BAX [BCL2-associated X protein], BCL2 [B-cell CLL/lymphoma 2], CALCA 14 
[Calcitonin-related polypeptide alpha], CASP1 [Caspase 1, apoptosis-related cysteine peptidase], 15 
COL18A1 [Collagen, type XVIII, alpha 1], ENG [Endoglin], F2R [Coagulation factor II (thrombin) 16 
receptor], HMOX1 [Heme oxygenase (decycling) 1], IL6 [Interleukin 6], ITGA5 [Integrin, alpha 5], 17 
PF4 [Platelet factor 4], PGF [Placental growth factor], PTGIS [Prostaglandin I2 synthase], VEGFA 18 
[Vascular endothelial growth factor A]); noteworthy, EDN1 [Endothelin 1] was expressed in only 3 19 
patients with a diagnosis of PA. The hierarchical clustering analysis is reported in Figure 2. After an 20 
initial unbiased transcriptional screening, we validated our results through a target gene approach; we 21 
performed qRT-PCR on 4 selected genes (CASP1, EDN1, F2R, HMOX1) in 10 patients with 22 
diagnosis of PA and 10 controls with EH. We selected the above-mentioned genes considering the 23 
expression profile in EVs and current available knowledge on their functional role. 24 
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After normalization for 18SrRNA expression and correction for the number of EVs per mL, we 1 
calculated the fold-change (FC) as the ratio between the RQ (Relative quantification coefficient) of 2 
PA and EH patients (Figure 3). CASP1 and EDN1 were up-regulated in patients with PA compared 3 
with patients with EH (FC = 12.0, P = 0.023 and FC = 18.3, P = 0.035, respectively), whereas we did 4 
not find significant differences for F2R and HMOX (FC = 9.1, P = 0.143 and FC = 2.4, P = 0.315, 5 
respectively). 6 
 7 
DISCUSSION 8 
In this study, we systematically characterized, for the first time, serum-derived EVs and analyzed 9 
their gene expression profile in patients affected by PA compared to controls with EH. The total 10 
number of EVs per mL, mainly derived from leucocytes and endothelial cells, was significantly 11 
higher in patients with PA and directly correlated with the aldosterone concentration; in addition, 12 
analyzing their mRNA cargo, we demonstrated the up-regulation of CASP1 and EDN1 in EVs derived 13 
from PA patients compared to those derived from patients with EH.  14 
In peripheral blood of healthy subjects, EVs mainly derive from platelets22; consistently with our 15 
results, the percentage of endothelial and inflammatory cell-derived EVs raises in pathological 16 
conditions such as atherosclerosis23. An increased number of circulating EVs has been reported in 17 
patients with acute coronary syndrome24, chronic renal failure25, diabetes26, and pre-eclampsia27. The 18 
concentration of endothelial- and platelet-derived EVs has been observed to be higher also in 19 
hypertensive patients compared to normotensive controls and the number of EVs per mL was 20 
proportional to systolic and diastolic BP28.  21 
In the present study, where patients with PA and EH were matched for blood pressure levels, patients 22 
with PA displayed a higher serum-derived EVs number compared with patients affected by EH; this 23 
observation could be due to a direct effect of the increased aldosterone levels on EVs number, or, 24 
alternatively, this could be the consequence of a more severe PA-associated endothelial damage. 25 
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Consequently, EVs could be considered as markers of endothelial dysfunction, or as mediators of 1 
vascular damage in patients with PA. In agreement with this hypothesis, the number of EVs per mL 2 
was directly related to aldosterone concentration.  3 
To further investigate the potential role of EVs in aldosterone-mediated endothelial damage, we 4 
performed a mRNA profiling analysis focused on genes involved in the regulation of endothelial 5 
function. Among genes differentially expressed in PA compared to EH patients, we confirmed by 6 
qRT-PCR in a larger cohort of patients, the up-regulation of CASP1 and EDN1 in EVs from patients 7 
with PA compared with patients with EH. 8 
CASP1 encodes for caspase-1, a cysteine-aspartic acid protease, which plays a central role in the 9 
execution-phase of apoptosis. Recently, some studies demonstrated the involvement of caspase-1 in 10 
aldosterone-induced vascular endothelial damage29 and renal tubulointerstitial fibrosis30,31, through 11 
in vitro and in vivo studies. Aldosterone infusion resulted in an increased expression of caspase-1 and 12 
two inflammasome components, ASC (Apoptosis-associated Speck-like protein Caspase-recruitment 13 
domain) and NLRP-3 (Nucleotide-binding domain, Leucine-Rich-containing family, Pyrin domain-14 
containing-3), whereas the mineralocorticoid receptor antagonist eplerenone reverted this effect30. 15 
The inflammasome complex activates caspase-1, which converts the precursors of IL-1β and IL-18 16 
to their active forms, inducing an inflammatory response32. Confirming these results, leukocytes from 17 
a healthy volunteer treated in vitro with aldosterone displayed an increased expression of NLRP-3 18 
and the activation of caspase-1 with increased levels of IL-1β in the supernatant29; moreover, serum 19 
IL-1β levels were significantly higher in patients with PA compared to healthy controls, and 20 
polymorphonuclear cells from the same subjects exhibited the up-regulation of NLRP-3 and an 21 
increased activity of caspase-129. 22 
Chronic inflammation mediated by inflammasome complex and caspase-1 has been described in 23 
atherosclerosis, diabetes, and chronic renal failure33-35 and may be responsible for an increased 24 
cardiovascular risk. Therefore, PA-derived EVs, carrying mRNA encoding for caspase-1, could be 25 
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associated with endothelial dysfunction and contribute to the increased cardiovascular risk observed 1 
in these patients19. 2 
EDN1 encodes a pre-pro-protein, which is processed through proteolysis in endothelial cells to the 3 
potent vasoconstrictor ET-1. ET-1 stimulates aldosterone production in vitro by primary culture of 4 
aldosterone-producing adenoma cells through binding to its receptors, ET-A and ET-B (Endothelin 5 
receptors Type A and B)36. Indeed, ET-1 was reported to be able to enhance angiotensin-II and 6 
ACTH-dependent up-regulation of CYP11B2, stimulating the synthesis of aldosterone37. On the other 7 
side, aldosterone induces the release of ET-1 from murine renal collecting duct cells through the 8 
epigenetic modification of chromatin structure around regulatory elements of EDN1, by MR 9 
activation38. In addition, murine models infused with aldosterone develop functional and structural 10 
vascular remodeling with increased levels of ET-1, systemic oxidative stress, tunica intima 11 
thickening, and deposition of collagen and fibronectin in the extra-cellular matrix8; spironolactone 12 
and an ET-A blocker prevented all these effects, suggesting that the detrimental action of aldosterone 13 
at vascular level is mediated not only by the aldosterone-mediated mineralocorticoid receptor 14 
activation but also by ET-1 and its receptors8. 15 
Nevertheless, the role of ET-1 in PA patients remains unclear; while some authors reported an 16 
increased production of aldosterone in subjects undergoing co-infusion of ACTH and ET-139, others 17 
did not find any difference in circulating levels of ET-1 in patients with PA compared to controls 18 
with EH40. Furthermore, there was no variation in the expression of genes encoding ET-1, ET-A, ET-19 
B, ECE-1 and ECE-2 (Endothelin-Converting Enzyme -1 and -2) in APA compared to normal adrenal 20 
glands41 and endothelial cells treated with aldosterone did not display differences in the expression 21 
of genes involved in renin-angiotensin-aldosterone system modulation, oxidative stress, and 22 
endothelial function42.  23 
Overall, studies attempting to demonstrate in humans a relationship between ET-1 and aldosterone-24 
mediated endothelial damage produced contrasting results. One of the reasons for the difficulty to 25 
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reproduce the aldosterone-mediated detrimental effects in an experimental model could be the lack 1 
of permissive conditions, such as the chronic exposure to elevated aldosterone concentrations and the 2 
simultaneous effects of high blood pressure levels, high sodium and low potassium levels, oxidative 3 
stress, pro-inflammatory, and pro-thrombotic stimuli42. In this perspective serum-derived EVs, being 4 
able to transfer EDN1 mRNA to endothelial cells, could represent one of the mediators of aldosterone-5 
dependent vascular injury. 6 
In conclusion, it is possible to speculate that concentration and content of EVs might reflect the 7 
increased endothelial damage displayed by patients with PA and that EVs can be actively involved 8 
in determining aldosterone-mediated vascular disease by delivering mRNA, cytokines, or other 9 
mediators.  10 
 11 
PERSPECTIVES 12 
Accumulating evidence highlights the contribution of EVs in the development of cardiovascular 13 
disease. For the first time we systematically characterized circulating EVs of patients diagnosed with 14 
PA compared to controls with EH. We found a significant correlation between serum aldosterone 15 
levels and EVs number and consistently a higher concentration of EVs in PA patients. PA-derived 16 
EVs are characterized by an enrichment of CASP1 and EDN1 transcripts, which encode for proteins 17 
involved in the pathogenesis of endothelial dysfunction and vascular damage. Therefore, a potential 18 
role for serum-derived EVs in determining the increased cardiovascular risk in PA can be 19 
hypothesized. Further in vitro and in vivo studies are warranted to investigate the potential functional 20 
and pathophysiological role of CASP1 and EDN1 overexpression and their link between aldosterone 21 
excess and endothelial dysfunction. 22 
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NOVELTY AND SIGNIFICANCE 10 
What is New?  11 
This is the first study which systematically characterizes PA patients serum-derived EVs compared 12 
to EVs from patients with EH, matched by age, gender and BP values, through the analysis of 13 
diameter, number, surface markers and mRNA expression profiling. 14 
What is Relevant? 15 
Our results demonstrate that PA compared to EH patients have a higher number of circulating EVs, 16 
mainly derived from leucocytes and endothelial cells, and whose concentration directly correlates 17 
with serum aldosterone levels. PA-derived EVs are enriched in CASP1 and EDN1 transcripts, 18 
suggesting their involvement in the development of endothelial dysfunction displayed by these 19 
patients. 20 
Summary 21 
PA affects 5-10% of hypertensive patients and is associated with an increased prevalence of 22 
cardiovascular events; endothelial dysfunction is considered a pre-clinical marker of aldosterone-23 
mediated cardiovascular disease.  24 
14 
 
Reflecting endothelial cells functional state, EVs could represent a marker of endothelial injury and 1 
also a mediator of the accelerated target organ damage, observed in patients with PA.  2 
15 
 
Table 1 – Patients characteristics 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
Legend to Table 1 – Clinical and biochemical characteristics of patients affected by PA (Primary 9 
Aldosteronism) or EH (Essential Hypertension). Sex (Male/Female) is expressed as absolute number. 10 
Age, Systolic BP (Blood Pressure), Diastolic BP and Potassium are reported as mean ± standard 11 
deviation. Aldosterone and PRA (Plasma Renin Activity) are reported as median [interquartile range].  12 
 13 
Figure 1 – Serum-derived extracellular vesicles (EVs) characterization 14 
Legend to Figure 1 – Characterization of serum-derived EVs from patients with a diagnosis of PA 15 
(Primary Aldosteronism; grey boxes) compared to patients with EH (Essential Hypertension; white 16 
boxes). (A) Diameter of EVs in nm at NTA (Nanoparticle Tracking Analysis); # P-value ≥ 0.05. (B) 17 
Quantification of EVs (EV n° per mL) at NTA; * P = 0.011 (C) FACS analysis for CD31, CD42b 18 
and CD45; the box plot represents the number of events in 60 seconds; # P ≥ 0.05; * P = 0.005; § P 19 
= 0.001. (D) Western Blot Analysis of CD63 (35-55 kDa), TSG101 (45 kDa) and Flotillin-1 (45 kDa); 20 
representative blots are shown for 4 patients with PA and 4 with EH. In panel A, B and C, the 21 
horizontal line indicates the median and box and bar represent the 25th to 75th and the 5th to 95th 22 
percentiles, respectively. 23 
 24 
Figure 2 – mRNA qRT-PCR-array profiling 25 
 PA (n = 12) EH (n = 12) P-value 
Sex (M/F) 8/4 8/4 1.000 
Age (years) 51 ± 8.0 50 ± 7.0 0.809 
Systolic BP (mmHg) 152 ± 13.2 150 ± 10.9 0.529 
Diastolic BP (mmHg) 94 ± 7.4 93 ± 6.9 0.700 
Potassium (mEq/L) 3.6 ± 0.4 4.3 ± 0.3 < 0.001 
Aldosterone (ng/dL) 28.3 [23.5 - 42.9] 9.4 [6.0 - 14.8] < 0.001 
PRA (ng/mL/h) 0.3 [0.1 - 0.6] 1.3 [0.8 - 3.8] < 0.001 
16 
 
Legend to Figure 2 – Heat map showing hierarchical cluster analysis of 63 genes expressed in serum-1 
derived EVs from patients with diagnosis of PA (Primary Aldosteronism) compared to patients with 2 
EH (Essential Hypertension). Up-regulated transcripts are reported in green and down-regulated 3 
transcripts in red, with darker shades for intermediate values. In black are represented not expressed 4 
genes. Patients are represented on columns (4 patients with PA on the left and 4 patients with EH on 5 
the right), whereas genes are represented on lines and labeled on the right. The log color scale is 6 
shown on the top. 7 
 8 
Figure 3 – qRT-PCR 9 
Legend to Figure 3 – Validation of gene expression profile by real-time PCR. TaqMan gene 10 
expression assays were used in qRT-PCR, performed in triplicate, to determine fold changes (FC) of 11 
expression levels in PA (Primary Aldosteronism; grey boxes; n = 10) patients compared to EH 12 
(Essential Hypertension; white boxes; n = 10). CASP1, EDN1, F2R and HMOX1 levels were 13 
evaluated using 18SrRNA as endogenous reference gene. RQ (Relative Quantification) are corrected 14 
for the n° of EVs/mL for each sample. # P ≥ 0.05; * P = 0.023; § P = 0.035. The horizontal line 15 
indicates the median and box and bar represent the 25th to 75th and the 5th to 95th percentiles, 16 
respectively.17 
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